Aspen Aerogels (ASPN) Expected to Announce Earnings on Thursday

Aspen Aerogels (NYSE:ASPN) will likely be releasing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Aspen Aerogels to post earnings of ($0.01) per share and revenue of $73.4150 million for the quarter. Aspen Aerogels has set its FY 2025 guidance at -3.860–3.730 EPS.Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Aspen Aerogels (NYSE:ASPN) last posted its quarterly earnings results on Thursday, August 7th. The construction company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.08. Aspen Aerogels had a negative net margin of 78.53% and a positive return on equity of 2.92%. The business had revenue of $78.02 million during the quarter, compared to analysts’ expectations of $72.53 million. During the same quarter in the prior year, the company posted $0.21 EPS. The business’s revenue for the quarter was down 33.8% on a year-over-year basis. On average, analysts expect Aspen Aerogels to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aspen Aerogels Stock Performance

Shares of ASPN stock opened at $7.85 on Thursday. The firm’s 50 day moving average price is $7.35 and its 200-day moving average price is $6.70. The company has a debt-to-equity ratio of 0.34, a quick ratio of 3.31 and a current ratio of 3.98. Aspen Aerogels has a one year low of $4.16 and a one year high of $18.95. The firm has a market cap of $646.28 million, a P/E ratio of -2.06 and a beta of 2.80.

Insider Transactions at Aspen Aerogels

In other Aspen Aerogels news, CAO Santhosh P. Daniel sold 4,410 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $7.31, for a total transaction of $32,237.10. Following the sale, the chief accounting officer directly owned 19,879 shares in the company, valued at $145,315.49. This represents a 18.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aspen Aerogels

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its holdings in shares of Aspen Aerogels by 89.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,274,356 shares of the construction company’s stock valued at $8,143,000 after purchasing an additional 602,586 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Aspen Aerogels by 105.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,246,506 shares of the construction company’s stock valued at $7,379,000 after purchasing an additional 639,753 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Aspen Aerogels by 1,045.5% in the 2nd quarter. Invesco Ltd. now owns 831,991 shares of the construction company’s stock valued at $4,925,000 after purchasing an additional 759,360 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Aspen Aerogels by 124.2% in the 2nd quarter. Bank of America Corp DE now owns 818,212 shares of the construction company’s stock valued at $4,844,000 after purchasing an additional 453,221 shares in the last quarter. Finally, HRT Financial LP raised its holdings in shares of Aspen Aerogels by 668.7% in the 2nd quarter. HRT Financial LP now owns 595,742 shares of the construction company’s stock valued at $3,526,000 after purchasing an additional 518,243 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on ASPN shares. Weiss Ratings restated a “sell (d)” rating on shares of Aspen Aerogels in a report on Wednesday, October 8th. Barclays lowered shares of Aspen Aerogels from an “equal weight” rating to an “underweight” rating and upped their price objective for the stock from $7.00 to $16.00 in a report on Monday, August 11th. Finally, Canaccord Genuity Group decreased their price objective on shares of Aspen Aerogels from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Aspen Aerogels currently has an average rating of “Hold” and an average target price of $15.50.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.